High-density lipoprotein cholesterol as a predictor of clinical outcomes in patients achieving low-density lipoprotein cholesterol targets with statins after percutaneous coronary intervention. Issue 23 (10th June 2011)

• Record Type: Journal Article
• Authors: Seo, Suk Min; Choo, Eun-Ho; Koh, Yoon-Seok; Park, Mahn Won; Shin, Dong Il; Choi, Yoon Seok; Park, Hun-Jun; Kim, Dong Bin; Her, Sung Ho; Lee, Jong Min; Park, Chul Soo; Kim, Pum-Joon; Moon, Keon Woong; Chang, Kiyuk; Kim, Hee Yeol; Yoo, Ki Dong; Jeon, Doo Soo; Chung, Wook Sung; Park, Yong Gyu; Seung, Ki-Bae
• Is Part Of: Heart. Volume 97:Issue 23(2011)
• Page Start: 1943
• Page End: 1950
• Publication Date: 2011-06-10
• Subjects: High-density lipoprotein cholesterol -- statin -- percutaneous coronary intervention -- drug eluting stents -- coronary angioplasty -- lipoproteins, coronary artery disease; Heart -- Diseases -- Treatment -- Periodicals; Cardiology -- Periodicals; 616.12
• DOI: 10.1136/hrt.2011.225466
• Languages: English
• ISSNs: 1355-6037

Abstract

Abstract : Background: A low level of high-density lipoprotein cholesterol (HDL-C) is strongly associated with cardiovascular events. However, the significance of HDL-C after statin therapy on the outcome of patients who have undergone percutaneous coronary intervention (PCI) with drug eluting stents (DES) is unclear. Objectives: To investigate the significance of HDL-C after statin therapy on cardiovascular events in patients with coronary artery disease after DES implantation. Methods: Patients who underwent PCI with DES from January 2004 to December 2009 were prospectively enrolled. The follow-up lipid panel of 2693 patients (median lab follow-up duration 225 days) who had continued using statins after PCI and who attained low-density lipoprotein cholesterol (LDL-C) <100 mg/dl was analysed. Major adverse cardiac events (MACE), including all-cause death, non-fatal myocardial infarction, and target vessel revascularisation according to follow-up HDL-C level (40 mg/dl for men or 50 mg/dl for women) were compared with the use of propensity scores matching. Results: Median follow-up duration was 832 days. 1585 (58.9%) patients had low follow-up HDL-C and 1108 had high follow-up HDL-C. The low follow-up HDL-C group had significantly higher rates of MACE. Low follow-up HDL-C was a significant independent predictor of MACE (adjusted HR 1.404, 95% CI 1.111 to 1.774, p=0.004). In further analysis with propensity scores matching, overall findings were consistent. Conclusions: Raising HDL-C levels may be a subsequent goal after achieving target LDL-C levels in patients with DES implantation.